Recent Updates
Recently added Catalysts
ENVB Positive Sentiment Score: 75/100

The Patent War That Wasn’t: How Enveric’s Legal Win Reframes the Neuroplastogen Race [Pharma Tech News]

Wednesday, February 25, 2026 1 min read
Key Takeaway: Enveric Biosciences announced a legal victory as a Post Grant Review petition against its U.S. Patent No. 12,138,276 was formally withdrawn. The petition was initially filed by Gilgamesh Pharmaceuticals and later inherited by AbbVie Inc. after its acquisition of Gilgamesh. This outcome potentially strengthens Enveric's position in the neuroplastogen market.
Price reaction · baseline $2.39 (2026-02-25T16:15:00.000Z) · hit during market hours · clean, no other ENVB news in the window
day 0 close · peak
+0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Enveric successfully defended its patent against a challenge.
  • The withdrawal of the petition strengthens Enveric's market position.
  • The legal win may enhance investor confidence in Enveric.

Full Press Release Details

In biotech, competitive lines are often drawn in the lab. Increasingly, they are drawn in patent court. This week, Enveric Biosciences announced that a Post Grant Review petition filed against its U.S. Patent No. 12,138,276 has been formally withdrawn. The petition, initially filed by Gilgamesh Pharmaceuticals, was later inherited by AbbVie Inc. following AbbVie’s acquisition of Gilgamesh in a transaction valued at up to 1.2 billion dollars centered on the clinical stage compound bretisilocin.
Full Article >>

Frequently Asked Questions

What was the outcome of the patent challenge against Enveric?

The Post Grant Review petition against Enveric's patent was formally withdrawn.

Who initially filed the petition against Enveric's patent?

The petition was initially filed by Gilgamesh Pharmaceuticals.

Which company inherited the patent challenge from Gilgamesh?

AbbVie Inc. inherited the petition following its acquisition of Gilgamesh.

What is the significance of this legal win for Enveric?

This legal victory strengthens Enveric's position in the neuroplastogen market.

Tags: ENVB Viatris Investor Conferences Healthcare Enveric Biosciences AbbVie Gilgamesh Pharmaceuticals bretisilocin neuroplastogen
Last updated: Feb 25, 2026

Biotech snapshot

Cash runway
$5M liquidity · $1M/mo burn
~4 mo
High dilution risk